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ABSTRACT 
Hepatitis C virus (HCV) is the major causative agent of chronic liver disease. Recently, the inhibition of NS3 RNA 
helicase/ATPase activity is being explored as the specifically targeted antiviral therapy (STAT) against HCV infection. This 
study was aimed to elucidate potential candidates for anti-HCV therapy derived from Indonesian indigenous microalgae. 
The microalga designated as BTM 11 was isolated and cultured. Methanol extract of BTM 11 was screened as the opponent 
of purified HCV NS3 RNA helicase enzyme through colorimetric ATPase assay. Screening of chemical compound and 
fractionation by using gel filtration chromatography with eluent of methanol : chloroform (1:99) were conducted for 
identification and isolation of the bioactive compounds. The third fraction of fractionated sample showed a relatively strong 
ATPase inhibitory effect (81.23 ± 2.25 %) compared to the negative control. Further analysis of third fraction using thin 
layer chromatography (TLC) with eluent of chloroform : methanol (9:2) gave two spots with the Rf value of 0.8 and 0.37, 
respectively. In addition, high performance liquid chromatography (HPLC) analysis showed absorption peak with the 
highest abundance at the retention time of 12.483 and 16.617 minutes which absorbed at 266 and 230 nm wavelenght, 
respectively. According to those analyses, this study suggests that bioactive compounds derived from BTM 11 were 
classified as the groups of flavonoids and feasible as potential candidates for anti-HCV therapy through the inhibitory effect 
of NS3 RNA helicase/ATPase activity. 
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ABSTRAK 
Virus Hepatitis C adalah penyebab utama penyakit hati kronis. Saat ini, penghambatan aktivitas NS3 RNA helikase/
ATPase sedang dieksplorasi sebagai target khusus untuk terapi antiviral melawan infeksi hepatitis C. Penelitian ini 
bertujuan untuk mengetahui kandidat yang berpotensi sebagai terapi anti-virus hepatitis C yang berasal dari mikroalga asli 
Indonesia. Mikroalga dengan kode BTM 11 telah berhasil diisolasi dan dikultur. Ekstrak metanol dari BTM 11 diskrining 
dan digunakan sebagai penghambat aktivitas enzim NS3 RNA helikase dari virus hepatitis C yang telah dimurnikan 
melalui uji kolorimetri ATPase. Penapisan senyawa kimia dan fraksinasi menggunakan gel filtration chromatography 
dengan eluen methanol : kloroform (1:99) dilakukan untuk identifikasi dan isolasi kandungan senyawa-senyawa bioaktif. 
Fraksi ketiga pada sampel fraksinasi menunjukkan efek inhibisi yang relatif kuat terhadap aktivitas ATPase (81.23 ± 2.25 
%) dibandingkan dengan kontrol negatif. Analisis lebih lanjut terhadap fraksi ketiga menggunakan kromatografi lapis tipis 
dengan eluen kloroform : metanol (9:2) menghasilkan dua noda yang mempunyai nilai Rf masing-masing 0,8 dan 0,37. 
Selanjutnya analisis high performance liquid chromatography (HPLC) menunjukkan serapan puncak dengan kelimpahan 
tertinggi pada waktu retensi 12,483 dan 16,617 menit dengan serapan panjang gelombang masing-masing 266 dan 230 nm. 
Hasil analisis penelitian ini menunjukkan bahwa senyawa bioaktif dari BTM 11 dikelompokkan dalam golongan flavonoid 
yang dapat berperan sebagai kandidat potensial untuk terapi anti-virus hepatitis C melalui efek inhibisi terhadap aktivitas 
NS3 RNA helikase/ATPase.  
 
Kata Kunci: Virus Hepatitis C, NS3 RNA helikase, ATPase, Mikroalga, Flavonoid 
INTRODUCTION 
 
The hepatitis C virus (HCV) is the member of 
genus Hepacivirus, family Flaviviridae. HCV is a 
small enveloped virus with the genome of a single-
strand of positive-sense RNA around 9.6 kb that 
consist of a 5’NTR, a long open reading frame 
(ORF) and a 3’NTR (Figure 1). The 5’NTR 
contains an internal ribosome entry site (IRES) 
mediating translation of a single polyprotein of 
approximately 3,000 amino acid residues. The 
polyprotein is cleaved by host and viral protease into 
at least 10 different products. The structural proteins 
(core, E1 and E2) are located in the amino terminus 
of the polyprotein followed by p7, a hydrofobic 
peptide with unknown function, and the non 
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marine organism, one of them is microalgae. 
Microalgae are primitive members of the plant 
kingdom with the approximate size of 3-20 μm. 
Some microalgae have been commercially 
produced as supplement food due to their high 
nutritional value such as, Spirulina, Chlorella, 
Dunaliella salina and Porphyridium (Chu 
2011). Microalgae also had potential activity as 
antiviral agents, although they are not fully 
explored. The methanol extracts of microalgae 
had been showed an antiviral activity against 
herpes simplex virus (HSV) and Epstein-Barr 
virus (EBV) (Ohta et al. 1998; Kok et al. 2011), 
while another study showed the polysaccharides 
fraction of red microalgae were found to inhibit 
the production of retroviruses (Talyshinsky et 
al. 2002). In addition, the isolate of Spirulina 
plantesis had been found to have anti-
enterovirus activity (Shih et al. 2003). 
Recent biotechnological advances and 
molecular approaches have led to the 
development of new antiviral strategies against 
HCV infection targeting specific HCV protein 
required for HCV replication such as NS2 
protease, NS3 helicase, NS3/4A protease, 
NS5A, and NS5B polymerase. NS3 helicase is a 
multifunctional protein with an N-terminal 
serine-type protease domain and a C-terminal 
RNA helicase/NTPase domain (Tai et al. 1996; 
Gallinari et al. 1998; Borowski et al. 2000; 
Soriano et al. 2009). In this study we devised a 
rational approach in the attempt to elucidate 
potential candidate of selective HCV NS3 RNA 
helicase inhibitors derived from Indonesian 
indigenous microalgae. This study may present 
an alternative way toward the development of 
therapeutic agent for chronic hepatitis C.  
 
MATERIAL AND METHODS 
 
Microalga BTM 11 were inoculated and 
grown into Modified Bristol Medium – Sea 
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Figure 1. Genome organization of Hepatitis C Virus. 
structural protein (NS2, NS3, NS4A, NS4B, NS5A 
and NS5B) (Hijikata et al. 1991; Grakoui et al. 1993; 
Bartenschlager et al. 2000).  
HCV is a major causative agent in most 
cases of acute and chronic non-A non-B 
hepatitis and could lead to liver-related diseases. 
Since the discovery of HCV in 1989, an 
estimated of 170 million people are persistently 
infected with HCV worldwide and the case 
number continues to increase (Choo et al. 1989; 
Kato et al. 1990; Takamizawa et al. 1991; WHO 
1999; Bartenschlager et al. 2000). Despite the fact 
that HCV infection commonly has sub-clinical or 
only associated with mild symptoms, persistent 
infection frequently progress to chronic hepatitis 
and may initiates steatosis, chirrosis, hepatocellular 
carcinoma and mortality in more than 70% of 
infected individual. Hepatocellular carcinoma is 
among the most lethal and prevalent cancers, 
and chronic HCV infection is one of the most 
prominent factors associated with this type of 
cancer (WHO 1999; Andrade et al. 2009). 
The global prevalence of HCV infection 
has become a significant health problem, 
however, the current standard therapy which 
combine pegylated-alfa interferon (PEG-IFNα) 
with ribavirin (RBV) is inadequately effective, 
poorly tolerated and can triggers some of 
adverse drug reactions such as flu-like symptomps, 
fatigue, severe malaise, hemolytic anemia, anorexia, 
taste disorders and depression (Manns et al. 2006; 
Jang et al. 2011). Furthermore, no effective vaccine 
for preventing HCV infection is available so far. 
Serious efforts are being made to develop an 
IFNα-free therapy to reduce the numerous side 
effect caused by the systemic administration of 
this cytokine. Thus, a novel and more effective 
therapeutic strategy is urgently required (Walker et 
al. 2003). 
The bioactive compounds isolated from marine 
organism often has potent biological activities. 
Indonesia is a country with mega biodiversity of 
 245 
Identification of Bioactive Compound from Microalga BTM 11 
 
Water (MBM-SW) medium by the measurement of 
OD630 within 50 days of cultivation with two days of 
observation interval, and harvested at lag-phase. 
Pellets were collected from 500 mL culture by 
centrifugation at 8500 rpm for 10 minutes. 
Extraction was carried out using organic solvent 
according to Ohta et al. 1998 by mixing the 
pellet with 80% MeOH followed by four cycles 
of sonication on ice (1 minute working, 2 minutes 
free) for cell disruption and the homogenate was 
centrifuged. The soluble fraction was vacuum 
evaporated at 60°C.  
The recombinant HCV NS3 RNA helicase 
protein was expressed and purified as described 
previously (Utama et al. 2000a). E. coli BL21 
(DE3)pLysS harboring expression plasmid 
(pET21b-466 amino acids of HCV NS3 RNA 
helicase gene) were cultured at 37°C in Luria-
Bertani medium containing 100 μg/ml of 
ampicillin. The protein expression was induced 
by the addition of 0.3 mM IPTG when the 
OD600 of the culture reached 0.3, for 3 hours. 
Following the induction, the cells were 
collected by centrifugation and three times of 
freezing and thawing, subsequently. Buffer B 
(10 mM Tris-HCl buffer (pH 8.5), 100 mM 
NaCl, 0.25% Tween 20) was used to resuspend 
the cells. Three cycles of sonication on ice (15 
seconds working, 1 minute free) were carried 
out to disrupt the cells. The soluble fraction of 
the clarified cell lysate was applied on buffer B-
calibrated TALON metal affinity resin 
(Clontech, Palo Alto, CA, USA) and the binding 
was carried out by gentle mixing for 3 hours at 
4°C. The resin-bound protein was collected by 
brief centrifugation followed by two times 
washing with buffer B. Buffer B containing 400 
mM imidazole was used to elute and purify the 
protein. The purified protein was confirmed by 
8% SDS-PAGE and visualized by coomassie 
blue staining.  
The inhibition of HCV NS3 RNA helicase/
ATPase activity was measured by colorimetric 
ATP hydrolysis assay based on the measurement of 
free phosphate moiety released from ATP, as 
described previously (Utama et al. 2000a). The 45 μl/
well of reaction mixture containing 10 mM 
MOPS buffer (pH 6.5), 2 mM ATP, 1 mM 
MgCl2, and purified HCV NS3 RNA helicase 
protein was incubated in the absence or 
presence of 5 μl methanol extract of microalgae 
in a 96 well microtiter plate at room temperature 
for 45 minutes. The reaction was stopped with 
the addition of 100 μl/well of dye solution (with 
the composition of water, 0.081% malachite 
green, 5.7% ammonium molybdate in 6N HCl, 
and 2.3% polyvinyl alcohol were 2:2:1:1, v/v). 
Following the addition of 25 μl/well of 30% 
sodium citrate, the absorbance at 620 nm was 
measured with the reference absorbance at 492 
nm. The inhibition rate was calculated as the 
percentage of absorbance in the presence of 
methanol extract as the inhibitory substance 
compared to absorbance in the absence of 
methanol extract. All absorbance measurements 
were done in triplicate and the results were 
expressed as mean value ± standard deviation. 
The chemical compouns present in the 
methanol extract of BTM 11 were identified by 
means of qualitative analysis according to the 
standard method (Harborne 1984). Alkaloids 
were identified by using Wagner’s, Mayer’s and 
Dragendorff’s test; tannins by treatment with 
1% (b/v) FeCl3; saponins by shaking with H2O; 
flavonoids by 10% (b/v) NaOH and 2N H2SO4; 
triterpenoid  and steroid by using Lieberman 
Buchard’s test.  
Purification of HCV NS3 RNA helicase 
inhibitor was performed as described by Ohta et 
al. 1998. The MeOH extract obtained will be 
fractionated on a column of silica gel using a 
solvent gradient of MeOH:CHCl3 (1:99). Then, 
the active fractions obtained were separated by 
TLC (Kieselgel 60, Merck) by using 
CHCl3:MeOH (9:2) as developing solvent. 
Next, this semi-purified sample subjected to 
HPLC on Eurospher (C18) column with 
MeOH:water (0:100; 33:67; 50: 50; 67: 33; 
100:0), flow rate 1 ml/1 minute, 254 nm.  
 
RESULTS 
 
Culture and extraction of microalgae 
Samples of microalgae were collected and 
isolated from various aquatic regions in 
Indonesia including Pari, Batam and Ciater. 
BTM 11, microalga isolated from Batam, was 
cultured and the growth was identified with the 
appearance of the green color filaments (Figure 
2). The culture of BTM 11 was harvested at lag-
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phase at 50 days of cultivation. Methanol was 
used as the polar solvent in the extraction 
method in order to obtain the chemical 
compound for the screening of NS3 RNA 
helicase/ATPase activity inhibitor.  
 
Expression and purification of the recombinant 
HCV NS3 RNA helicase protein 
The purified recombinant HCV NS3 RNA 
helicase protein were confirmed by SDS-PAGE 
8% as shown in Figure 3. The confirmed size 
was 54 kDa. The enzymatic activities of the 
HCV NS3 RNA helicase purified protein were 
used for the colorimetric ATPase assay. 
 
ATPase assay 
The crude methanol extract of BTM 11 
showed highly stable ATPase inhibitory effect 
compare to the other isolate (data not shown). 
The inhibition activities of the fractionated 
crude methanol extract of BTM 11 were 
represented as percentages in Table 1. The third 
fraction showed the highest inhibitory effect 
(81.23 ± 2.25 %). 
 
Phytochemical studies 
The screening result for phytochemical test 
of the methanol extract of BTM 11 were 
recorded in Table 2. The results indicated the 
presence of flavonoids group in polar solvent 
(methanol and distiller water).  
 
Purification and identification of HCV NS3 
RNA helicase inhibitor 
The third fraction which showed high 
inhibition activity (81.23 ± 2.25 %) were 
pooled, and dialyzed. The purity of each 
preparation step was confirmed by TLC. The 
TLC assay showed that the third fraction have 
two spots with Rf 0.8 and 0.37 (Figure 4). 
Further chemical analysis was conducted using 
HPLC. Based on qualitative analysis using 
profiling chemical compound, the third fraction 
showed two peaks and had high abundance with 
retention time (Rt) at 12.483 minutes and 16.617 
minutes (Figure 5). Two selected peaks were 
analyzed with PDA detector. The retention time 
12.483 minutes was absorbed at 266 nm 
wavelength, while the retention time 16.617 
minutes was absorbed at 230 nm wavelength 
(Figure 6 and Figure 7).  According to Harbone 
(1984), the two absorbance results indicate that 
the bioactive compounds derived from the third 
fraction were classified as the group of 
flavonoids.  
 
DISCUSSION 
 
Based on the sequence motif analysis, the 
HCV NS3 protein was predicted as multifunctional 
protein containing serine protease, NTPase, and 
RNA helicase activities. The HCV NS3 RNA 
helicase/NTPase domain is classified into the 
DexH protein subfamily of the helicase 
superfamily II which is capable of unwinding 
RNA-RNA duplexes by disrupting the hydrogen 
bonds fueled by ATP hydrolysis during viral 
transcription and/or replication. (Tai et al. 1996; 
Gallinari et al. 1998; Borowski et al. 2000; 
Utama et al. 2000a; Utama et al. 2000b). 
Although the NS3 helicase represent an ideal 
candidate as the specifically targeted antiviral 
therapy, but the progress is lack behind other 
viral enzymes such as NS3/NS4 protease, NS5A 
protein and NS5B polymerase. In term of HCV 
therapy, two protease inhibitors (telaprevir and 
boceprevir) are expected to receive final approval for 
clinical use, while no helicase inhibitors have been 
completed the preclinical test (Belon & Frick, 
2009; Soriano et al. 2011). 
Screening of the chemical compounds 
followed by isolation of the bioactive compound 
might be one of the strategies for the development of 
helicase inhibitors. These compounds could 
proceed as lead molecules for analog synthesis, 
 
Figure 2. Microalga BTM 11 (1000x).  
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structure-activity studies, and possible identification 
of a novel drug design. However, measuring helicase
-catalyzed RNA unwinding is difficult since the 
reaction products (single-stranded RNA) will 
rapidly re-anneal, thus, cannot be detected.  
In this study, we perform a simple 
spectrophotometry method by monitoring the 
free phosphate moiety as the result of helicase-
catalyzed ATP hydrolysis using colorimetric 
ATPase assay. Based on the color spectrum, 
higher inhibitory effect will be shown as lower 
color intensity. The results showed that the third 
fraction of fractionated sample derived from 
methanol extract of microalgae BTM 11 had the 
highest inhibitory effect compare to the negative 
control.  
Microalgae frequently live in extreme 
environments of light, salinity, and temperature. 
In order to adapt to these extreme conditions, 
most of them produce a high variety of secondary 
metabolites that often have potent biological 
activities. In comparison with terrestial plants, 
microalgae can be easily cultured in the 
laboratory scale with appropiate cultivation 
condition to provide a consistent source of bioactive 
compounds, however, the composition of bioactive 
compounds derived from microalgae might vary 
depends on the species (Ibañez et al. 2012). 
The phytochemical analysis, TLC and 
HPLC result showed that the chemical inhibitor 
of HCV RNA helicase in this study belongs to 
the group of flavonoids. Flavonoid is one of the 
phenolic compound that had been extensively 
studied and known to have abundance structures. 
Another studies also showed the presence of 
flavonoid in the extract of microalgae by using new 
detection method of ultra high performance 
liquid chromatography tandem mass spectrometry 
(UHPLC-MS/MS) technology (Klejdus et al. 2010; 
Goiris et al. 2014). 
The exploration of flavonoid regarding to 
its antiviral activity was mostly targeting HIV 
infection, but recently, flavonoid also known to 
have antiviral activity against herpes simplex 
virus, coxsackievirus B3 and also dengue virus 
(Tapas et al. 2008; Yin et al. 2014; Qamar et al. 
2014; de Sousa et al. 2015). However, most of 
these studies are performed in vitro, and less 
information about in vivo studies of antiviral 
activity of flavonoid are known.  
Flavonoid acts as inhibitor against HCV 
infection through several modes of action such 
as the inhibition of RNA binding of HCV RNA 
dependent-RNA polymerase (Ahmed-Belkacem, et 
al. 2014) and decreasing HCV mature 
microRNA122 levels (Shibata et al., 2014). In this 
study, the specific mechanisms of action of the 
identified flavonoid are not precisely determined. 
However, the approach use in this study was 
based on the fact that the ATP hydrolysis 
provides the energy for the RNA unwinding 
reaction. The inhibition of the accessibility of 
the helicase-ATP binding site for the ATP may 
 1 Fraction % Inhibition  
1 64.85 ± 3.73 
2 71.70 ± 5.66 
3 81.23 ± 2.25 
4 67.63 ± 1.41 
5 62.21 ± 7.57 
6 58.79 ± 8.96 
7 27.70 ± 9.71 
8 53.70 ± 6.32 
9 56.95 ± 2.91 
10 46.14 ± 4.13 
Figure 3. SDS-PAGE analysis of Hepatitis C Virus 
NS3 RNA helicase with approximately 54 
kDa in size. 
Table 1. Inhibition of HCV NS3 RNA helicase/
ATPase activity by the coloumn 
chromatography fractionated samples. 
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lead to the reduction of ATPase activity and 
consequently declining the unwinding rate, 
which hampered the viral replication. Furthermore, 
according to Borowski et al. 2002, inhibitor of 
HCV RNA helicase/NTPase could act by 
several mechanisms such as, obstruction of NTP 
binding; inhibition through allosteric mechanism; 
inhibition of the coupling of NTP hydrolysis; 
competitive inhibition of RNA binding and also 
sterical blockade of the translocation of the 
helicase/NTPase along polynucleotide chain 
during unwinding stage.  
It appears that the flavonoids derived from 
the methanol extract of microalga BTM 11 have 
great potential as antiviral therapy, particularly 
 1 
Chemical 
Compound 
Identification 
Alkaloids  
- Wagner - 
- Meyer - 
- Dragendorf - 
Tannin - 
Saponin - 
Flavonoid  + 
Triterpenoid  - 
Steroid - 
Table 2. Qualitative identification of chemical 
compound of  BTM 11 methanol extract.  
 
2      3     4  
4 
2      3     4  
4 
  
Rf  0.8 
Rf  0.37 
Figure 4. TLC of the third fraction. (a) spot detec-
tion with heat treatment, (b) spot detection 
with UV 254 nm.  
Figure 5. Chromatogram of the third fraction using HPLC. 
Figure 6. The retention time 12.483 minutes was ab-
sorbed at 266 nm wavelength 
Figure 7.  The retention time 16.617 minutes was ab-
sorbed at 230 nm wavelength. 
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for anti-HCV infection. Nevertheless, further 
isolation, purification, characterization, and 
modification as well as molecular study of the 
bioactive compounds need to be done in the 
attempt to obtain higher antiviral activity. 
Furthermore, the mechanism of antiviral effect 
and in vivo study remain to be elucidated.   
 
CONCLUSION 
 
As the concluding remarks, this study 
suggests that the extraction of bioactive 
compounds derived from microalga BTM 11 
which is classified as the groups of flavonoids, 
showed potential activity against HCV infection 
through the inhibitory effect of NS3 RNA 
helicase/ATPase activity. 
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